Coherus offloads Humira biosimilar Yusimry for $40m [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
The moves come as Coherus plans to become an oncology-only focused company. To that end, the company also sold its ophthalmology portfolio to Sandoz for $170m in January. The sale included Cimerli (ranibizumab-eqrn), a biosimilar to Roche's Lucentis, which has been approved for a variety of retinal indications including wet age-related macular degeneration, diabetic macular oedema, and diabetic retinopathy. Following the deal conclusion, HKF's US subsidiary, Meitheal Pharmaceuticals will have exclusive commercial rights to Yusimry in the US. The companies have invested in expanding their biologics portfolio and capabilities in recent years. In September 2023, Meitheal acquired the US rights to three insulin biosimilars from China-based Tonghua Dongbao Pharmaceutical. The US approval for these biosimilars is expected in 2026. Yusimry is a tumour necrosis factor (TNF) blocker and has been approved for nine indications – to reduce the signs and symptoms of rheumatoid arthritis, juve
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Oncolytic Viruses: Unlocking a New Era in Cancer Immunotherapy | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Trends in biopharma: the future of manufacturing [Yahoo! Finance]Yahoo! Finance
- Global Muscle Relaxant Drugs Market Size To Worth USD 5.91 Billion By 2033 | CAGR Of 4.24% [Yahoo! Finance]Yahoo! Finance
- 1 Dividend Growth Stock to Buy and Hold for 10 Years [Yahoo! Finance]Yahoo! Finance
- Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at Argus from $300.00 to $340.00. They now have a "buy" rating on the stock.MarketBeat
AMGN
Earnings
- 5/2/24 - Beat
AMGN
Sec Filings
- 6/21/24 - Form 11-K
- 6/21/24 - Form 11-K
- 6/12/24 - Form S-8
- AMGN's page on the SEC website